- {{heading}}
- Ab00786-15.0 Anti-GM2 ganglioside [L55-81]
- Human
- Human IgM
- Purified
- In Stock
- Ab00786-23.0 Anti-GM2 ganglioside [L55-81]
- Human
- Rabbit IgG
- Purified
- In Stock
Recombinant monoclonal antibody to GM2 ganglioside. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma L55-81.
Immunogen: L55-81 was prepared by isolating EBV-immortalized peripheral blood B lymphocytes from a human donor with melanoma.
Specificity: L55-81 binds specifically to GM2 ganglioside; this antibody shows no reactivity towards GM1, GM3, GD2 or normal tissues- the L55-81 epitope contains both a GalNAc and sialic acid bound to lactose. Ganglioside GM2 (GalNAcβ1-4(NeuNAcα2-3)Galβ1-4Glcβ-1ceramide) is a glycosphingolipid present on the cell surface and a major tumor-differentiation antigen in human melanoma and hepatoma.
Application Notes: L55-81 reacts positively to melanoma cell lines with high GM2 expression (M14; M24), and shows no binding to normal cell types or cell lines M15 or M25 which have low GM2 expression and high GM3 expression. This specificity can be confirmed by ELISA and TLC immunostaining by testing a variety of gangliosides and neutral glycolipids. L55-81 is able to lyse cells from the M14 melanoma cell line (which has high GM2 expression) in the presence of human or rabbit complement, but not in the absence of complement - this was shown by a [51Cr] release assay. Biotinylated L55-81 has been used for IHC of acetone-fixed sections of tumor tissue in an avidin-biotin complex immunoperoxidase system. Statistically significant positive staining (determined by Fisher's exact test) was displayed with melanoma, colon carcinoma and ovary carcinoma tumor tissues. Staining has also be observed with breast carcinoma, prostate carcinoma and kidney carcinoma.
Antibody first published in:
Nishinaka et al. Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment. Cancer Res. 1996 Dec 15;56(24):5666-71. PMID:8971173
Note on publication:
Describes the establishment of an anti-GM2 cell line L55-81 and its action against tumors such as by its anti-tumor activity and its ability to stain tumor sections.
Immunofluorescence staining of fixed MCF7 cells with anti-GM2 ganglioside antibody L55-81 (Ab00786) Immunofluorescence analysis of paraformaldehyde fixed MCF7 cells on Shi-fix™ coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of L55-81 (Ab00786-23.0) at 10 µg/ml for 1h followed by Alexa Fluor® 488 secondary antibody (1 µg/ml), showing diffuse membrane and cytoplasmic staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom Ab00786-23.0, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody (Ab102-23.0) followed by Alexa Fluor® 488 secondary antibody.